

New scientific leadership to spearhead S*BIO's drug discovery R&D efforts

3 November 2003, Singapore. S*BIO has received a strong boost in scientific capabilities with three significant new staff appointments. Dr. Michael Entzeroth joined S*BIO in April 03, as Chief Scientific Officer. He is responsible for charting the company's scientific direction. Dr. Entzeroth has some 20 years of industry experience in the drug development arena, involving both scientific research and management. Prior to S*BIO, he has held senior positions in pharmaceutical companies in Europe. He has also consulted for the German Ministry of Research and was a member of the scientific advisory board of the International Symposium on Laboratory Automation and Robotics 2002.

Dr. Entzeroth will be speaking at the Biomedical Research Applications in Drug Discovery Technology Asia Pacific Congress on 5 November, at the Shangri-La Hotel. His presentation, entitled "*Where Chemistry and Biology meet – Accelerating the Drug Discovery Process*", will highlight how the environment should be structured and integrated with various technologies, during the start up and growth of a company, so as to have the biggest impact on the speed of the discovery process.

*"The last 6 months at S*BIO have been very exciting for me. With an internationally experienced research team on board, we have prioritised our activities and also generated a promising target portfolio. The foundations for successful R&D operations has been laid and I am looking forward to working with the team to discover innovative drug candidates for S*BIO's proprietary programs"* said Dr. Michael Entzeroth.

S*BIO also welcomes two new heads of Departments, Dr. Eric Sun and Dr. Ni Binhui, as Head of Chemistry and Head of Biology, respectively. Both bring with them years of scientific and industry experience, helping to strengthen S*BIO's scientific position. Dr Sun heads S*BIO's Medicinal Chemistry and Analytics

research groups, which aim to discover and develop pre-development candidates. Prior to S*BIO, Dr. Sun has worked on research programs in opiates, cancer and metabolic diseases. His medicinal chemistry responsibilities spanned lead generation to pre-clinical candidate selection. Dr. Ni provides leadership and direction for the Biology research groups within the company. Dr. Ni has some 15 years international experience gained through working in China, Canada and the United States. He has also authored numerous peer-reviewed manuscripts in the fields of molecular pharmacology, neurosciences and drug discovery.

The senior research management team also includes Dr. Brad Carte, who is the Head of R&D Coordination at S*BIO. Dr Carte is responsible for planning and coordinating S*BIO's research projects and also oversees the company's strategic collaborations and outsourcing needs. With 18 years experience in the pharmaceutical industry, Dr. Carte has developed in-depth knowledge in the fields of synthetic and natural product chemistry, high throughput screening, drug development and R&D management.

About S*BIO

S*BIO is Singapore's first and only fully integrated small molecule drug discovery company, formed through a partnership between the Singapore Economic Development Board Investments (EDBI) and Chiron Corporation. Under a technology license agreement, S*BIO leveraged on Chiron's small molecule drug discovery platform, gene expression database, cancer focused target databases and chemical compound libraries. S*BIO currently has 56 employees (46 in R&D) and has occupied a state-of-the-art 22,000 sq ft facility at the Singapore Science Park II since January 2002.

S*BIO's R&D capabilities encompass the entire drug discovery process, from target validation, through to early pre-clinical development. S*BIO's international team of researchers, with strong industry backgrounds, are highly experienced in the areas of functional genomics, protein biochemistry, assay development, high throughput screening, combinatorial and medicinal chemistry, computational



Company Regn No: 200004639G

chemistry, lead optimization biology, pharmacology, in vitro ADMET
characterization and drug discovery informatics.

For more information, please visit S*BIO's website, www.sbio.com, or contact:

Chan Yiu Lin

PR Consultant

S*BIO

Email: pr@sbio.com

Mobile: (65) 9-765 5897